Dihydropyrimidine dehydrogenase deficiency in an Indian population
- 105 Downloads
Background: Dihydropyrimidine dehydrogenase (DPD) deficiency is prevalent in 3–5% of the Caucasian population; however, the frequency of this pharmacogenetic syndrome in the Indian population and other racial and ethnic groups remains to be elucidated. Patients and methods: We describe an Indian patient who presented to clinic for the treatment of gastric adenocarcinoma with 5-flurouracil (5-FU) therapy who subsequently was diagnosed with DPD deficiency by using the peripheral blood mononuclear cell (PBMC) DPD radioassay. This observation prompted us to examine the data generated from healthy (cancer-free) Indian subjects who were enrolled in a large population study to determine the sensitivity and specificity of the uracil breath test (UraBT) in the detection of DPD deficiency. Thirteen Indian subjects performed the UraBT. UraBT results were confirmed by PBMC DPD radioassay. Results: The Indian cancer patient demonstrated reduced DPD activity (0.11 nmol/min/mg protein) and severe 5-FU toxicities commonly associated with DPD deficiency. Of the 13 Indian subjects [ten men and three women; mean age, 26 years (range: 21–31 years)] enrolled in the UraBT, 12 Indian subjects demonstrated UraBT breath profiles and PBMC DPD activity within the normal range; one Indian subject demonstrated a reduced breath profile and partial DPD deficiency. Conclusions: DPD deficiency is a pharmacogenetic syndrome which is also present in the Indian population. If undiagnosed, the DPD deficiency can lead to death. Future epidemiological studies would be helpful to determine the prevalence of DPD deficiency among racial and ethnic groups, allowing for the optimization of 5-FU chemotherapy.
KeywordsDihydropyrimidine dehydrogenase (DPD) enzyme 5-Fluoruracil (5-FU) Fluoropyrimidine DPD deficiency Indian Race
This work was supported in part by NIH grant CA 62164.
- 1.Meta-analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537–3541Google Scholar
- 2.Van Kuilenburg AB et al (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101(3):253–258Google Scholar
- 13.Mattison LK et al (2005) Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Proceedings of the 2005 ASCO Annual Meeting 2005:2004Google Scholar
- 17.Harris BE et al (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197–201PubMedGoogle Scholar
- 18.Meretek Diagnostics I (2002) In: Meretek UBiT-IR300: 13CO2 urea breath analyzer instruction manual. Lafayette, CO, Meretek Diagnostics, pp A1–A2Google Scholar
- 30.Ezzeldin HH et al (2005) Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11(24) (in press)Google Scholar